





| Passport No : | LABORATORY TEST REP | PORT |
|--|--|---|
| Patient Information | Sample Information | Client/Location Information |
| Name : Lyubochka Svetka | Lab ld : 02232160XXXX | Client Name : Sterling Accuris Buddy |
| Sex/Age : Male / 41 Y 01-Feb-1982 | Registration on : 20-Feb-2023 09:10 Collected at : non SAWPL | Location : |
| Ref. ld : | Collected on : 20-Feb-2023 08:53 | Approved on : 20-Feb-2023 11:09 Status : Final Printed On : 28-Feb-2023 10:26 |
| Ref. By : | Sample Type : EDTA Blood | Process At : 1. NRL SAWPL Gujarat Ahmedabad Paldi |

Complete Blood Count

| Test Hemoglobin | Colorimetric | Result 14.5 | Unit g/dL | Biological Ref. Interval 13.0 - 16.5 |
|--------------------|-----------------------|----------------|---------------------|--|
| RBC Count | Electrical impedance | 4.79 | million/cmm | 4.5 - 5.5 |
| Hematocrit | Calculated | 43.3 | % | 40 - 49 |
| MCV | Derived | 90.3 | fL | 83 - 101 |
| МСН | Calculated | 30.2 | pg | 27.1 - 32.5 |
| МСНС | Calculated | 33.4 | g/dL | 32.5 - 36.7 |
| RDW CV | Calculated | 13.60 | % | 11.6 - 14 |
| otal WBC and Diffe | rential Count | | | |
| WBC Count | SF Cube cell analysis | 10570 | /cmm | 4000 - 10000 |
| ifferential Count | | | | Absolute Count |
| Neutrophils | Microscopic | 73 | % 40 - 80 | 7716 /cmm 2000 - 6700 |
| Lymphocytes | Microscopic | 19 | % 20 - 40 | 2008 /cmm 1100 - 3300 |
| Eosinophils | Microscopic | 02 | % 1 - 6 | 211 /cmm 00 - 400 |
| Monocytes | Microscopic | 06 | % 2 - 10 | 634 /cmm 200 - 700 |
| Basophils | Microscopic | 00 | % 0 - 2 | 0 /cmm 0 - 100 |
| Platelet Count | Electrical impedance | 150000 | /cmm | 150000 - 410000 |
| MPV | Calculated H | 14.00 | fL | 7.5 - 10.3 |

Peripheral Smear Examination

RBC Morphology Normochromic Normocytic

WBC Morphology WBCs Series Shows Normal Morphology

Platelets Morphology Platelets are adequate with normal morphology.

Parasites Malarial parasite is not detected.

Erythrocyte Sedimentation Rate

ESR 0 - 14 mm/1hr Capillary photometry

DR.TEJASWINI DHOTE

M.D. Pathology

Dr. Sanjeev Shah

MD Path

Dr. Yash Shah

MD Path

This is an Electronically Authenticated Report.

Referred Test

Page 1 of 19





| Passport No : | LABORATORY TEST REP | ORT |
|--|---|---|
| Patient Information | Sample Information | Client/Location Information |
| Name : Lyubochka Svetka | Lab Id : 02232160XXXX | Client Name : Sterling Accuris Buddy |
| Sex/Age : Male / 41 Y 01-Feb-1982 Ref. ld : Ref. By : | Registration on : 20-Feb-2023 09:10 Collected at : non SAWPL Collected on : 20-Feb-2023 08:53 Sample Type : EDTA Blood, Serum | Location : Approved on : 20-Feb-2023 13:33 Status : Final Printed On : 28-Feb-2023 10:26 Process At : 1. NRL SAWPL Gujarat Ahmedabad Paldi |

Blood Group

Test Result Unit Biological Ref. Interval

"A" ABO Type

Rh (D) Type Positive

DR.TEJASWINI DHOTE

M.D. Pathology

Dr. Sanjeev Shah

MD Path

Dr. Yash Shah

MD Path

This is an Electronically Authenticated Report.

Referred Test

Page 2 of 19







| Passpo | ort No : | LABORA | 4 T | ORY TEST REP | PORT | |
|-------------------------------|---------------------|---------------------------|------------|--|---|---------------------------------------|
| | Patient Information | Samp | ole | Information | | Client/Location Information |
| Name | : Lyubochka Svetka | Lab Id | : | 02232160XXXX | Client Name | : Sterling Accuris Buddy |
| Sex/Age Ref. Id Ref. By | : | Collected at Collected on | : : | 20-Feb-2023 09:10 non SAWPL 20-Feb-2023 08:53 Serum | Approved or Printed On Process At | : : : : : : : : : : : : : : : : : : : |

| | | | _ |
|---|-----|------|-----|
| | ᆔ | Draf | :1~ |
| ᆫ | DIU | Prof | пе |

| | Lipid i ioi | iie - | |
|--|-----------------|-------|---|
| Test | Result | Unit | Biological Ref. Interval |
| Cholesterol Cholesterol oxidase – Peroxidase method | 189.0 | mg/dL | Desirable : <200 Borderline High : 200-239 High : >240 |
| Triglyceride Ezymatic (Lipase/GK/GPO/POD) | H 168.0 | mg/dL | Normal : <150 Borderline : 150-199 High : 200-499 Very High : >500 |
| HDL Cholesterol | 60.0 | mg/dL | Low: <40.0 High: >60.0 |
| Direct LDL Direct measured | H 100.39 | mg/dL | Optimal: <100 Near to above Optimal: |
| | | | 100–129 Borderline High: 130-159 High: 160–189 Very High: =190 |
| VLDL Calculated | 33.60 | mg/dL | 15 - 35 |
| CHOL/HDL Ratio | 3.1 | | Up to 5.0 |
| LDL/HDL Ratio | 1.7 | | Up to 3.5 |

P.O

Dr. Purvish Darji

Dr. Sanjeev Shah

Dr. Yash Shah

MD(Path)

MD Path

MD Path

This is an Electronically Authenticated Report.

Referred Test

Page 3 of 19







| Passport | t No : | LABOR | PORT | | | |
|----------|----------------------------------|--------------------|------|--------------------------------|-----------------------------|---|
| | Patient Information | Sample Information | | | Client/Location Information | |
| Name | : Lyubochka Svetka | Lab Id | : | 02232160XXXX | Client Name | e : Sterling Accuris Buddy |
| Sex/Age | : Male / 41 Y 01-Feb-1982 | _ | | 20-Feb-2023 09:10 | Location | : |
| | : | Collected at | | non SAWPL 20-Feb-2023 08:53 | Approved or Printed On | 1 : 20-Feb-2023 11:45 Status : Final : 28-Feb-2023 10:26 |
| Ref. By | : | Sample Type | · \: | Fluoride plasma | Process At | : 1. NRL SAWPL Gujarat Ahmedabad Paldi |

Biochemistry

Test Result Unit Biological Ref. Interval Fasting Blood Sugar H 141.0 74 - 106 mg/dL

P.D

Dr. Purvish Darji

MD(Path)

Dr. Sanjeev Shah

MD Path

Dr. Yash Shah

MD Path

This is an Electronically Authenticated Report.

Referred Test

Page 4 of 19







| Passport | No: | LABOR | RAT | REPORT | | |
|----------|----------------------------------|--------------|--------------------|--------------------------------|---------------------------|---|
| F | Patient Information | | Sample Information | | | Client/Location Information |
| Name | : Lyubochka Svetka | Lab Id | : | 02232160XXXX | Client Name | e : Sterling Accuris Buddy |
| Sex/Age | : Male / 41 Y 01-Feb-1982 | _ | | 20-Feb-2023 09:10 | Location | : |
| | : | Collected at | | non SAWPL 20-Feb-2023 08:53 | Approved or Printed On | 1 : 20-Feb-2023 11:33 Status : Final : 28-Feb-2023 10:26 |
| Ref. By | : | Sample Type | : | EDTA Blood | Process At | : 1. NRL SAWPL Gujarat Ahmedabad Paldi |

HbA1c (Glycosylated Hemoglobin)

| TIDATE (Clycosylated Helloglobili) | | | | | | | |
|---|---------------|-------|--|--|--|--|--|
| Test | Result | Unit | Biological Ref. Interval | | | | |
| HbA1c High Performance Liquid Chromatography | H 7.10 | % | For Screening: Diabetes: >6.5% Pre-Diabetes: 5.7% - 6.4% Non-Diabetes: < 5.7% For Diabetic Patient: Poor Control: > 7.0 % Good Control: 6.0-7.0 % | | | | |
| Mean Blood Glucose | 157.07 | mg/dL | | | | | |

Explanation:-

- Total haemoglobin A1 c is continuously synthesized in the red blood cell throught its 120 days life span. The concentration of HBA1c in the cell reflects the average blood glucose concentration it encounters.
- The level of HBA1c increases proportionately in patients with uncontrolled diabetes. It reflects the average blood glucose concentration over an extended time period and remains unaffected by short-term fluctuations in blood glucose levels.
- The measurement of HbA1c can serve as a convenient test for evaluating the adequacy of diabetic control and in preventing various diabetic complications. Because the average half life of a red blood cell is sixty days, HbA1c has been accepted as a measurement which reflects the mean daily blood glucose concentration, better than fasting blood glucose determination, and the degree of carbohydrate imbalance over the preceding two months.
- · It may also provide a better index of control of the diabetic patient without resorting to glucose loading procedures.

HbA1c assay Interferences:

Erroneous values might be obtained from samples with abnormally elevated quantities of other Haemoglobins as a result of either their simultaneous elution with HbA1c (HbF) or differences in their glycation from that of HbA (HbS).

Reference: ADA Guideline 2023

Thote.

DR.TEJASWINI DHOTE

M.D. Pathology

Dr. Sanjeev Shah

This is an Electronically Authenticated Report.

MD Path

Dr. Yash Shah

MD Path

VID I atti

Referred Test

Page 5 of 19







| Passport No : | | LABORATORY TEST REPORT | | | | |
|---------------------|---------------|---------------------------|------|--------------------------------|--------------------------|---|
| Patient Info | rmation | Sai | mple | Information | | Client/Location Information |
| Name : Lyubochl | a Svetka | Lab Id | : | 02232160XXXX | Client Name | : Sterling Accuris Buddy |
| Sex/Age : Male / 41 | Y 01-Feb-1982 | \ • | | 20-Feb-2023 09:10 | Location | : |
| Ref. ld : | 011001002 | Collected at Collected or | | non SAWPL 20-Feb-2023 08:53 | Approved on | |
| Ref. By : | | Sample Typ | е : | Serum | Printed On Process At | : 28-Feb-2023 10:26 : 1. NRL SAWPL Gujarat Ahmedabad Paldi |

Thyroid Function Test

| Test | Result | Unit | Biological Ref. Interval | |
|-----------------------------------|--------|------------|--------------------------|--|
| T3 - Trijodothyronine | 1.01 | ng/mL | 0.58 - 1.59 | |
| T4 - Thyroxine | 7.84 | mg/mL | 4.87 - 11.72 | |
| TSH - Thyroid Stimulating Hormone | 0.8199 | microIU/mL | 0.35 - 4.94 | |

| TSH | T3/FT3 | T4/FT4 | Suggested Interpretation for the Thyroid Function Tests Pattern |
|---------------------------|---------------------------|---------------------------|---|
| Within Range | Decreased | Within Range | Isolated Low T3-offen seen in elderly & associated Non-Thyroidal illiness. In elderly the drop in T3 level can be upto 25% |
| Raised | Within Range | Within Range | Isolated High TSH especially in the range of 4,7 to 15 mIU/ml is commonly associated with physiological & Biological TSH Variability. Subclinical Autoimmune Hypothyroidism Intermited T4 therapy for hypothyroidism Recovery phase after Non-Thyroidal itiness |
| Raised | Decreased | Decreased | Chronic autoimmune Thyroiditis Post thyroidectomy, Post radioiodine Hypothyroid phase of transient thyroiditis |
| Raised or Within Range | Raised | Raised or Within range | Interfering antibodies to thyroid hormones (anti-TPO antibodies) Intermittent T4 therapy or T4 overdose Drug interference-Amiodarone, Heparin, Beta blockers, steroids, anti-epileptics |
| Decreased | Raised or within Range | Raised or within Range | Isolated Low TSHF - especially in the range of 0.1 to 0.4 offen seen in elderly & associated with Non-Thyroidal lifness Subclinical Hyperthyroidism Thyroxine ingestion |
| Decreased | Decreased | Decreased | Central Hypothyroidism Non-Thyroidal illness Recent treatment for Hyporthyroidism (TSH remains suppressed) |
| Decreased | Raised | Raised | Primary Hyperthyroidism (Graves disease), Multinodular goitre Toxic nodule Transient thyroiditis:Postpartum, Silent (lymphocytic), Postviral (granulomatous, subacute, DeQuervain'a) Gestational thyrotoxicosis with hyperemesis gravidarum |
| Decreased or within range | Raised | Within Range | - T3 toxicosis - Non-Thyroidal illness |

P.O

Dr. Purvish Darji

Dr. Sanjeev Shah

Dr. Yash Shah

MD(Path)

MD Path

MD Path

This is an Electronically Authenticated Report.

Referred Test

Page 6 of 19







| Passport No : | LABOR | RAT | ORY TEST REF | PORT | | |
|-----------------------|-------------|--------------------|--------------|--------------------------------|------------------------|---|
| Patient Information | | Sample Information | | | | Client/Location Information |
| Name : Lyubochka | Svetka | Lab Id | : | 02232160XXXX | Client Name | : Sterling Accuris Buddy |
| Sex/Age : Male / 41 Y | 01-Feb-1982 | _ | | 20-Feb-2023 09:10 | Location | : |
| Ref. Id : | 011661302 | Collected at | | non SAWPL 20-Feb-2023 08:53 | Approved on Printed On | : 20-Feb-2023 12:40 Status : Final : 28-Feb-2023 10:26 |
| Ref. By : | | Sample Type | e : | Urine | Process At | : 28-Feb-2023 10:26 : 1. NRL SAWPL Gujarat Ahmedabad Paldi |

Biochemistry

| Test | Result | Unit | Biological Ref. Interval |
|---------------------------------|--------|------|--------------------------|
| Microalbumin (per urine volume) | 10.50 | mg/L | < 16.7 |

In random urine specimens, normal urinary albumin excretion is below 17 mg/g creatinine for males and below 25 mg/g creatinine for females.(3) Microalbuminuria is defined as an albumin:creatinine ratio of 17 to 299 for males and 25 to 299 for females.

A ratio of albumin:creatinine of 300 or higher is indicative of overt proteinuria.

Due to biologic variability, positive results should be confirmed by a second, first-morning random or 24-hour timed urine specimen. If there is discrepancy, a third specimen is recommended. When 2 out of 3 results are in the microalbuminuria range, this is evidence for incipient nephropathy and warrants increased efforts at glucose control, blood pressure control, and institution of therapy with an angiotensin-converting-enzyme (ACE) inhibitor (if the patient can tolerate it).

Reference:

- Bennett PH, Haffner S, Kasiske BL, et al: Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations
 to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the Council on Diabetes Mellitus of the National
 Kidney Foundation. Am J Kidney Dis 1995;25:107-112
- Krolewski AS, Laffel LM, Krolewski M, et al: Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med 1995;332:1251-1255
- 3. Zelmanovitz T, Gross JL, Oliveira JR, et al: The receiver operating characteristics curve in the evaluation of a random urine specimen as a screening test for diabetic nephropathy. Diabetes Care 1997;20:516-519

P.O

MD(Path)

Dr. Purvish Darji

Dr. Sanjeev Shah

Dr.Yash Shah

Referred Test

MD Path

MD Path

Page 7 of 19

This is an Electronically Authenticated Report.







| Passport | No: | LABORA | ٩T | ORY TEST REF | PORT | |
|---------------------|--------------------|------------------------------|----|---|----------------------------------|--|
| Patient Information | | Sample Information | | | Client/Location Information | |
| Name | : Lyubochka Svetka | Lab Id | : | 02232160XXXX | Client Name | : Sterling Accuris Buddy |
| Sex/Age | | Collected at Collected on | : | 20-Feb-2023 09:10 non SAWPL 20-Feb-2023 08:53 | Location Approved on Printed On | : 20-Feb-2023 11:41 Status : Final : 28-Feb-2023 10:26 |
| Ref. By | : | Sample Type | : | Serum | Process At | : 1. NRL SAWPL Gujarat Ahmedabad Paldi |

Protein

| | 1 1000111 | | | |
|--|-----------|-------|--------------------------|--|
| Test | Result | Unit | Biological Ref. Interval | |
| Total Protein Copper tartrate to colour complex | 7.00 | g/dL | 6.3 - 8.2 | |
| Albumin Bromocresol Green Method | 4.20 | g/dL | 3.5 - 5.0 | |
| Globulin Calculated | 2.80 | g/dL | 2.3 - 3.5 | |
| A/G Ratio Calculated | 1.50 | | 1.3 - 1.7 | |
| | Bilirubi | in | | |
| Total Bilirubin Azobilirubin chromophores | 0.70 | mg/dL | 0.2 - 1.3 | |
| Conjugated Bilirubin Cationic Mordant Binding | 0.30 | mg/dL | 0.0 - 0.3 | |
| Unconjugated Bilirubin Cationic Mordant Binding | 0.20 | mg/dL | 0.0 - 1.1 | |
| Delta Bilirubin Calculated | 0.20 | mg/dL | 0.0 - 0.2 | |
| | | | | |

P.D

Dr. Purvish Darji

MD(Path)

Dr. Sanjeev Shah

MD Path

Dr. Yash Shah

MD Path

This is an Electronically Authenticated Report.

Referred Test

Page 8 of 19







| Passport No : | LAB | ORAT | ORY TEST REF | PORT |
|----------------------------|--------------------|--------|--------------------------------|---|
| Patient Information | | Sample | Information | Client/Location Information |
| Name : Lyubochka Svetka | Lab Id | : | 02232160XXXX | Client Name : Sterling Accuris Buddy |
| Sex/Age : Male / 41 Y 01-I | Feb-1982 Collected | | 20-Feb-2023 09:10 non SAWPL | Location |
| Ref. ld : Ref. By : | Collected Sample | | 20-Feb-2023 08:53 Serum | Approved on : 20-Feb-2023 11:29 Status : Final Printed On : 28-Feb-2023 10:26 Process At : 1. NRL SAWPL Gujarat Ahmedabad Paldi |

Iron Studies

| | ii oii otaa | 100 | | |
|------------------------------------|-------------|------------|-----------------------------------|---|
| Test | Result | Unit | Biological Ref. Interval | _ |
| Iron Pyridyl azo Dye | 103.00 | micro g/dL | 49 - 181 | |
| Total Iron Binding Capacity (TIBC) | 352.00 | | 261 - 462 | |
| Transferrin Saturation Calculated | 29.26 | % | Children : >16 Adult : 20 - 50 | |

P.D

Dr. Purvish Darji

Dr. Sanjeev Shah

Dr. Yash Shah

MD(Path)

MD Path

MD Path

This is an Electronically Authenticated Report.

Referred Test

Page 9 of 19







| Passport No : LABORATORY TEST REP | | | | | | PORT | |
|-----------------------------------|--------------------|-------------|--------|------|--|-----------------------------------|---|
| Patient Information | | | Sam | ıple | Information | | Client/Location Information |
| Name | : Lyubochka Sve | etka | Lab Id | : | 02232160XXXX | Client Name | : Sterling Accuris Buddy |
| | : Male / 41 Y : | 01-Feb-1982 | _ | : | 20-Feb-2023 09:10 non SAWPL 20-Feb-2023 08:53 Serum | Approved on Printed On Process At | : 20-Feb-2023 11:38 Status : Final : 28-Feb-2023 10:26 : 1. NRL SAWPL Gujarat Ahmedabad Paldi |

Immunoassav

Test Result Unit Biological Ref. Interval Homocysteine, Serum H 23.86 6.0 - 14.8micromol/L

Summary and Uses:

- Total Hcy is a thiol-containing amino acid, produced by the intracellular demethylation of methionine to
- Elevated levels of t Hcy may be used to exclude or confirm deficiencies of vitamin B12 or folate.
- It is recommended to test in patients using medications that interfere with folate status (methotrexate, antiepileptics), vegetarians without B12 supplementations, unexplained anemia, peripheral neuropathy or myleopathy, recurrent spontaneous abortions or infertility.
- Testing also recommended for patients 40 years of age with coronary artery disease to exclude homocystinuria.
- Elevations in tHcy levels have also been used as an independent risk factor of coronary or cerebral vascular disease. Treatment of moderate hyperhomocystinemia with folic acid supplementation for primary and secondary cardiovascular protection has met with inconsistent results and at present cannot be routinely recommended.

Limitations:

- The plasma must be seprated immediately on collection to avoid continuous synthesis of Hcy by red cells.
- Samples must be immediately stored on ice and serum centrifuged immediately before a complete clot is
- Certain drugs, such as anticonvulsants, methotrexate, or nitrous oxide, may interfere with the assay.
- Cigarette smoking and coffee consumption increase tHcy levels.
- Intraindividual variability is approximately 8%; it can be as much as 25% in patients with hyperhomocystinemia.
- Generally, a single measurement of tHcy is considered adequate.

D.O

MD(Path)

Dr. Purvish Darji

Dr. Sanjeev Shah

This is an Electronically Authenticated Report.

Dr. Yash Shah MD Path

MD Path

Referred Test

Page 10 of 19







| Passport No : LABORATORY TEST REP | | | | | | |
|-----------------------------------|--------------------|--------------------|---|--|---|--|
| Patient Information | | Sample Information | | | | Client/Location Information |
| Name | : Lyubochka Svetka | Lab Id | : | 02232160XXXX | Client Name | : Sterling Accuris Buddy |
| Sex/Age Ref. Id Ref. By | : | - | : | 20-Feb-2023 09:10 non SAWPL 20-Feb-2023 08:53 Serum | Location Approved or Printed On Process At | : n : 20-Feb-2023 11:10 Status : Final : 28-Feb-2023 10:26 : 1. NRL SAWPL Gujarat Ahmedabad Paldi |

Biochemistry

| | | _ | |
|--|---------------|-----------------|--------------------------|
| Test | Result | Unit | Biological Ref. Interval |
| Creatinine, Serum Creatinine Amidohydrolase | 0.83 | mg/dL | 0.66 - 1.25 |
| Urea Urease, Colorimetric | L 18.0 | mg/dL | 19.3 - 43.0 |
| Blood Urea Nitrogen Calculated | L 8.41 | mg/dL | 9.0 - 20.0 |
| Uric Acid Uricase | 4.90 | mg/dL | 3.5 - 8.5 |
| Calcium Arsenazo III | 9.10 | mg/dL | 8.4 - 10.2 |
| SGPT UV with P5P, IFCC | 48.0 | U/L | 0 - 50 |
| SGOT UV with P5P | 27.0 | U/L | 17 - 59 |
| | Electro | olytes | |
| Sodium (Na+) Direct- ISE | 143.00 | mmol/L | 136 - 145 |
| Potassium (K+) Direct- ISE | 4.90 | mmo l /L | 3.5 - 5.1 |
| Chloride (CI-) Direct- ISE | 105.0 | mmo l /L | 98 - 107 |

Pie

Dr. Purvish Darji

MD(Path)

Dr. Sanjeev Shah

Dr. Yash Shah

MD Path

MD Path

This is an Electronically Authenticated Report.

Referred Test

Page 11 of 19







| Passport No : LABORATORY TEST REP | | | | | | |
|-----------------------------------|----------------------------------|---------------------------|---|--------------------------------|--------------------------|--|
| Patient Information | | Sample Information | | | | Client/Location Information |
| Name | : Lyubochka Svetka | Lab Id | : | 02232160XXXX | Client Name | : Sterling Accuris Buddy |
| Sex/Age | : Male / 41 Y 01-Feb-1982 | | | 20-Feb-2023 09:10 | Location | : |
| | : Wate 7 41 1 01-1 65-1302 | Collected at Collected on | | non SAWPL 20-Feb-2023 08:53 | Approved on | : 20-Feb-2023 12:33 Status : Final |
| | : | Sample Type | : | Serum | Printed On Process At | : 28-Feb-2023 10:26: 1. NRL SAWPL Gujarat Ahmedabad Paldi |

Immunoassay

Test Result Unit Biological Ref. Interval
25(OH) Vitamin D 8.98 ng/mL Deficiency : <10

Insufficiency: 10 - 30 Sufficiency: 30 - 100 Toxicity: >100

Vitamin D is a fat soluble vitamin and exists in two main forms as cholecalciferol(vitamin D3) which is synthesized in skin from 7-dehydrocholesterol in response to sunlight exposure & Ergocalciferol(vitamin D2) present mainly in dietary sources. Both cholecalciferol & Ergocalciferol are converted to 25(OH)vitamin D in liver.

Interpretation:

Increased In

- · Vitamin D intoxication
- Excessive exposure to sunlight

Decreased In

- Malabsorption
- Steatorrhea
- Dietary osteomalacia, anticonvulsant osteomalacia
- · Biliary and portal cirrhosis
- Thyrotoxicosis
- · Pancreatic insufficiency
- Celiac disease
- Rickets
- Alzheimer disease

Limitations:

More recently, it has become clear that receptors for vitamin D are present in a wide variety of cells and that this hormone has biologic effects extending beyond the control of mineral metabolism. Vitamin D deficiency is not clear. Levels needed to prevent rickets and osteomalacia (15 ng/mL) are lower than those that dramatically suppress parathyroid hormone levels (20–30 ng/mL). In turn, those levels are lower than levels needed to optimize intestinal calcium absorption (34 ng/mL). Neuromuscular peak performance is associated with levels approximately 38 ng/mL. A recent study states that increasing mean baseline levels from 29 to 38 ng/mL was associated with a 50% lower risk for colon cancer and levels of 52 ng/mL with a 50% reduction in the incidence of breast cancer. It is recommended to have clinical correlation with serum 25(OH)vitamin D, serum calcium, serum PTH & serum alkaline phosphatase.

Thote

DR.TEJASWINI DHOTE

M.D. Pathology

Dr. Sanjeev Shah

Dr. Yash Shah

MD Path

MD Path

This is an Electronically Authenticated Report.

Referred Test

Page 12 of 19







| Passpor | t No : | LABORA | TORY | TEST REF | PORT |
|---------------------|--------------------|--------------------|----------|-------------|--|
| Patient Information | | Sample Information | | | Client/Location Information |
| Name | : Lyubochka Svetka | Lab Id | : 02232 | 160XXXX | Client Name : Sterling Accuris Buddy |
| Sex/Age | | Collected at | : non SA | | Approved on : 20-Feb-2023 12:04 Status : Final |
| | : | | : Serum | -2023 06.53 | Printed On : 28-Feb-2023 10:26 Process At : 1. NRL SAWPL Gujarat Ahmedabad Paldi |

Immunoassay

Test Result Unit Biological Ref. Interval Vitamin B12 L < 148 pg/mL 187 - 833

Vitamin B12 is essential in DNA synthesis, hematopoiesis, and CNS integrity.

Interpretation:

- Increased In : Chronic granulocytic leukemia , COPD and Chronic renal failure , Leukocytosis , Liver cell damage (hepatitis, cirrhosis) , Obesity and Severe CHF, Polycythemia vera, Protein malnutrition.
- **Decreased In**: Abnormalities of cobalamin transport or metabolism, Bacterial overgrowth, Crohn disease, Dietary deficiency (e.g. in vegetarians) , Diphyllobothrium (fish tapeworm) infestation , Gastric or small intestine surgery , Hypochlorhydria , Inflammatory bowel diseas , Intestinal malabsorption and Intrinsic factor deficiency

Limitations:

- Drugs such as chloral hydrate increase vitamin B12 levels. On the other hand, alcohol, aminosalicylic acid, anticonvulsants, ascorbic acid, cholestyramine, cimetidine, colchicines, metformin, neomycin, oral contraceptives, ranitidine, and triamterene decrease vitamin B12 levels.
- The evaluation of macrocytic anemia requires measurements of both vitamin B12 and folate levels; ideally they should be measured simultaneously.
- Specimen collection soon after blood transfusion can falsely increase vitamin B12 levels.
- Patients taking vitamin B12 supplementation may have misleading results.
- A normal serum concentration of B12 does not rule out tissue deficiency of vitamin B12. The most sensitive test for B12 deficiency at the cellular level is the assay for MMA. If clinical symptoms suggest deficiency, measurement of MMA and homocysteine should be considered, even if serum B12 concentrations are normal.

DR.TEJASWINI DHOTE

M.D. Pathology

Dr. Sanjeev Shah

MD Path

MD Path

Dr. Yash Shah

This is an Electronically Authenticated Report.

Referred Test

Page 13 of 19







| Passpoi | rt No : | LABORA | PORT | | |
|---------------------|----------------------------------|--------------------|------|--------------------------------|--|
| Patient Information | | Sample Information | | | Client/Location Information |
| Name | : Lyubochka Svetka | Lab Id | : | 02232160XXXX | Client Name : Sterling Accuris Buddy |
| Sex/Age | : Male / 41 Y 01-Feb-1982 | - | | 20-Feb-2023 09:10 non SAWPL | Location : |
| Ref. Id | : | Collected on | | 20-Feb-2023 08:53 | Approved on : 20-Feb-2023 11:38 Status : Final Printed On : 28-Feb-2023 10:26 |
| Ref. By | : | Sample Type | : | Serum | Process At : 1. NRL SAWPL Gujarat Ahmedabad Paldi |

Immunoassay

Test Result Unit Biological Ref. Interval **PSA-Prostate Specific Antigen, Total** 0.573 0 - 4ng/mL

PSA is a glycoprotein that is expresses by both normal and neoplastic prostate tissue and is prostate tissue specific and not prostate cancer specific. PSA is constantly expressed in nearly all prastate cancers, although its level of expression on a percell basis is lower than in normal prostate epithelium. The absolute value of serum PSA is useful for determining the extent of prostate cancer and assessing the response to prostate cancer treatment; its use as a screening method to detect prostate cancer is also common.

Interpretation

Increased in

- Prostate disease (Cancer, Prostatitis, Benign prostatic hyperplasia, Acute urinary retention)
- Manipulations (Cystoscopy, Needle biopsy, Radiation therapy, Indwelling catheter, Prostatic massage)
- Transurethral resection
- Prostatic ischemia

Decreased in

- Castration
- Prostatectomy
- Radiation therapy
- Ejaculation withi 24 48 hours
- 5-alpha-reductase inhibitor reduces PSA by 50% after 6 months in men without cancer

Limitations

- PSA has been recommended by the American Cancer Society for use in conjunction with a DRE for early detection of prostate cancer starting at the age of 50 years for men with at least 10 year life expectancy
- PSA levels that are measured repeatedly over time may vary because of biologic variability where the true PSA level in a given man is different on different measurements.
- A change in PSA of >30% in man with a PSA initially below 2.0 ng/mL was likely to indicate a true change beyond normal random variation.

Did.

MD(Path)

Dr. Purvish Darji

Dr. Sanjeev Shah

Dr. Yash Shah

MD Path

MD Path

This is an Electronically Authenticated Report.

Referred Test

Page 14 of 19





| Passport No : | LABORATORY TEST REP | ORT |
|--|--|--|
| Patient Information | Sample Information | Client/Location Information |
| Name : Lyubochka Svetka | Lab ld : 02232160XXXX | Client Name : Sterling Accuris Buddy |
| Sex/Age : Male / 41 Y 01-Feb-1982 | Registration on : 20-Feb-2023 09:10 Collected at : non SAWPI | Location : |
| Ref. ld : | Collected at : non SAWPL Collected on : 20-Feb-2023 08:53 | Approved on : 20-Feb-2023 12:06 Status : Final |
| Ref. By : | Sample Type : Serum | Printed On : 28-Feb-2023 10:26 Process At : 1. NRL SAWPL Gujarat Ahmedabad Paldi |

Immunoassay

| Test | Result | Unit | Biological Ref. Interval |
|------------|-----------------|-------|--------------------------|
| IgE CHA | H 492.30 | IU/mL | 0 - 87 |

IgE mediates allergic and hypersensitivity reactions. There is a significant overlap in total IgE between allergic and nonallergic individuals. Interpretation:

- Increased In
 - Atopic diseases
 - Exogenous asthama in approximately 60% of patients
 - Hay fever in approximately 30% of patients and Atopic eczema
 - Influenced by type of allergen, duration of stimulation. Presence of symptoms, and hyposensitization treatment
 - Parasitic diseases (e.g. ascariasis, visceral larva migrans, hookworm disease, schistosomiasis, Echinococcus infestation)
 - Monoclonal IgE myeloma

- Decreased In

- Hereditary deficiencies
- Acquired immunodeficiency
- Ataxia-telangiectasis
- Non-IgE myeloma

Limitations:

- A normal level of IgE in serum does not eliminate the possibility of allergic disease.
- Serum total IgE levels for the majority of individuals with IgE-mediated disease can be expected to be elevated compared to the reference range for healthy adults. However, not all allergic patients exhibit elevated serum total IgE levels.
- Since not all atopic reactions are IgE-mediated, a total IgE result in the reference range should always be interpreted in light of other clinical
- Heterophilic antibodies in human serum can react with the immunoglobulins included in the assay components causing interference with in vitro immunoassays.

Did.

MD(Path)

Dr. Purvish Darji

Dr. Sanjeev Shah

Dr. Yash Shah

MD Path

MD Path

This is an Electronically Authenticated Report.

Referred Test

Page 15 of 19







| Passport No : LABORATORY TEST REPORT | | | | |
|--|---|---|--|--|
| Patient Information | Sample Information | Client/Location Information | | |
| Name : Lyubochka Svetka | Lab ld : 02232160XXXX | Client Name : Sterling Accuris Buddy | | |
| Sex/Age : Male / 41 Y 01-Feb-1982 | Registration on : 20-Feb-2023 09:10 Collected at : non SAWPI | Location : | | |
| Ref. ld : | Collected at : non SAWPL Collected on : 20-Feb-2023 08:53 Sample Type : Serum | Approved on : 20-Feb-2023 14:35 Status : Final Printed On : 28-Feb-2023 10:26 | | |
| | ' '' | Process At : 1. NRL SAWPL Gujarat Ahmedabad Paldi | | |

| Test | Result | Unit | Biological Ref. Interval |
|------------------------------|--------------|------|--|
| HIV I & II Ab/Ag with P24 Ag | 0.070 | S/Co | Non Reactive : <1.0 Reactive : >1.0 |
| Interpretation | Non Reactive | | |
| HBsAg Chemiluminescence | 0.290 | S/Co | Non Reactive : <1.0 Reactive: >1.0 |
| Interpretation | Non Reactive | | |

Additional Information:

- A NON REACTIVE result implies that no Anti HIV-1 or HIV-2 antibodies have been detected in the sample by this method. This means that either the patient has not been exposed to HIV-1 or HIV-2 infection or the sample has been tested during the "WINDOW PHASE" (before the development of detectable levels of antibodies).
- A PROVISIONALITY REACTIVE / BORDERLINE REACTIVE result suggests possibility of HIV-1 or/and HIV-2 infection. However these results must be verified by confirmatory WESTERN BLOT / HIV PCR method before declaring the patient positive for HIV-1 or HIV-2 infection.
- Very high levels of IgM Antibodies or Anti-HLA ABC and DR Antibodies can give false positive reaction.

**Pre & Post test counselling for HIV testing is responsibility of reffering Physician.

Dr. Siddharth Thummar

M.D. Pathology

Dr. Sanjeev Shah

MD Path

Dr. Yash Shah

MD Path

This is an Electronically Authenticated Report.

Referred Test

Page 16 of 19







| Passpor | t No : | | LABOR | RAT | ORY TEST REF | PORT | |
|---------|---------------------|-------------|------------------------------|------|---------------------------------|-------------|--|
| | Patient Information | on | San | nple | Information | | Client/Location Information |
| Name | : Lyubochka Sve | etka | Lab Id | : | 02232160XXXX | Client Name | : Sterling Accuris Buddy |
| Sex/Age | : Male / 41 Y | 01-Feb-1982 | \ | | 20-Feb-2023 09:10 | Location | i |
| Ū | | 01-160-1302 | Collected at Collected on | | non SAWPL | Approved on | : 20-Feb-2023 14:16 Status : Final |
| | : | | | 1 | 20-Feb-2023 08:53 EDTA Blood | Printed On | : 28-Feb-2023 10:26 |
| Ref. By | : | | Sample Type | ; | EDTA DI000 | Process At | : 1. NRL SAWPL Gujarat Ahmedabad Paldi |

HB Electrophoresis By HPLC

Instrument Name: BIORAD VARIANT - II Haemoglobin Testing System

| Test | Result | Unit | Biological Ref. Interval | |
|----------------|---------------------|---------------------------|--------------------------|--|
| Hb A | L 84.4 | % | 96.8 - 97.8 | |
| Hb A2 | 2.8 | % | 2.2 - 3.2 | |
| P2 Peak | 5.5 | % | | |
| P3 Peak | 5.2 | % | | |
| Foetal Hb | 0.3 | % | 0.0 - 1.0 | |
| Interpretation | Negative for typica | l beta thalassemia trait. | | |

Interpretation:

- All results have to be correlated with age and history of blood transfusion if there is history of blood transfusion in last 3 months, repeat testing after 3 month from last date of transfusion is recommended.
- In case of haemoglobinopathy, parents or family studies and councelling is advised.
- This test detects beta thalassaemia and haemoglobinopathies, DNA analysis is recommended to rule out alpha thalassaemia and silent
- Linearity range of HbF is 1-40%, However, values in excess of the reportable range have been provided for ease of interpretation.
- Mild to moderate increase in fetal haemoglobiin can be seen in some acquired condition like pregnancy, megaloblastic anaemia, Throtoxicosis, Hypoxia, Chronic kidney disease, Recovering marrow, MDS, Aplastic anaemia, PNH, Medications (Hydrocyurea, Erythropoietin) ect.
- P3 window-Above 10% is often indicative of either denatured froms of hemoglobins or may suggest a possibility of abnormal haemoglobin variant. Hence, repeat analysis with fresh sample or DNA studies is advised.
- P2 Window-Above 10% is indicative of either glycated haemoglonin requring correlation with diabetic staus or may suggest a possibility of abnormal haemoglobin variant further DNA studies for confirmation.

Dr. Hardik Modi

Dr. Sanjeev Shah

Dr. Yash Shah

Hematopathologist (G-18097)

MD Path

This is an Electronically Authenticated Report.

MD Path

Page 17 of 19 # Referred Test

Bio-Rad CDM System VII Inst. #1. SN-13939



Patient Data

Sample ID: 022321600126

Patient ID:

Name:

Physician:

Sex: DOB:

Comments:

Analysis Data

Analysis Performed: 02/20/2023 13:56:59

Injection Number: 2575
Run Number: 95
Rack ID: 0001
Tube Number: 2

Report Generated: 02/2

Operator ID:


02/20/2023 14:04:40

| | Calibrated | | Retention | Peak |
|-----------|------------|--------|------------|---------|
| Peak Name | Area % | Area % | Time (min) | Area |
| Unknown | | 0.1 | 1.00 | 2400 |
| F | 0.3 | | 1.08 | 8321 |
| Unknown | | 1.6 | 1.18 | 44109 |
| P2 | | 5.5 | 1.30 | 148807 |
| Р3 | | 5.2 | 1.72 | 139183 |
| Ao | | 84.4 | 2.34 | 2277592 |
| A2 | 2.8 | | 3.64 | 76999 |

Total Area: 2,697,411

F Concentration = 0.3 % A2 Concentration = 2.8 %

Analysis comments:









| Passport No: LABORATORY TEST REPORT | | | |
|--|--|---|--|
| Patient Information | Sample Information | Client/Location Information | |
| Name : Lyubochka Svetka | Lab Id : 02232160XXXX | Client Name : Sterling Accuris Buddy | |
| Sex/Age : Male / 41 Y 01-Feb-1982 | Registration on : 20-Feb-2023 09:10 Collected at : non SAWPL | Location : | |
| Ref. ld : | Collected on : 20-Feb-2023 08:53 Sample Type : Urine | Approved on : 20-Feb-2023 11:12 Status : Final Printed On : 28-Feb-2023 10:26 Process At : 1. NRL SAWPL Gujarat Ahmedabad Paldi | |

| Test | Result | Unit | Biological Ref. Interval |
|---|--------------|------|--------------------------|
| hysical & Chemical (Dip strip) exami | nation | | |
| Colour | Pale Yellow | | Pale Yellow |
| Clearity | Clear | | Clear |
| pH Double indicator | 6.0 | | 4.6 - 8.0 |
| Specific Gravity Polyelectrolyte based reaction | 1.030 | | 1.005 - 1.030 |
| Urine Glucose GOD-POD | Present (+) | | Absent |
| Urine Protein Protein error of indicators | Absent | | Absent |
| Bilirubin Diazo reaction | Absent | | Absent |
| Urobilinogen Modified Ehrlich reaction | Absent | | Absent |
| Urine Ketone Nitroprusside | Absent | | Absent |
| Nitrite Nitrite reaction | Absent | | Absent |
| licroscopic Examination | | | |
| Pus Cells | 1-2 | | Absent |
| Red Cells | Nil | /hpf | 0 - 2 |
| Epithelial Cells | 1-2 | /hpf | |
| Casts | Absent | /hpf | Absent |
| Crystals | Absent | /hpf | Absent |
| Amorphous Material | Absent | | |
| | | | |
| | End Of Repor | t | |

DR.TEJASWINI DHOTE

M.D. Pathology

Dr. Sanjeev Shah

MD Path

Dr. Yash Shah

MD Path

This is an Electronically Authenticated Report.

Referred Test

Page 19 of 19